Michael Wacker
Fondatore presso LimmaTech Biologics AG
Profilo
Michael Wacker was the founder of GlycoVaxyn AG (founded in 2004) and LimmaTech Biologics AG (founded in 2015), where he held the titles of Chief Scientific Officer and Director, respectively.
He currently holds positions as Chairman at Inositec AG, Non-Executive Director at Scenic Biotech BV, and Member-Supervisory Board at Tubulis GmbH.
His former positions include Director & Chief Business Officer at Polyneuron Pharmaceuticals AG and Principal at Swiss Federal Institute of Technology.
Dr. Wacker received his undergraduate and doctorate degrees from Swiss Federal Institute of Technology.
Posizioni attive di Michael Wacker
| Società | Posizione | Inizio |
|---|---|---|
Inositec AG
 Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Presidente | - |
Tubulis GmbH
 Tubulis GmbH Pharmaceuticals: MajorHealth Technology Tubulis GmbH engages in biotechnology company. The firm develops matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company was founded by Dominik Schumacher and Jonas Helma-Smets and is headquartered in Munich, Germany. | Direttore/Membro del Consiglio | - |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Fondatore | 01/01/2015 |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Michael Wacker
| Società | Posizione | Fine |
|---|---|---|
| Swiss Federal Institute of Technology | Corporate Officer/Principal | - |
Polyneuron Pharmaceuticals AG
 Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Direttore/Membro del Consiglio | - |
GlycoVaxyn AG
 GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Fondatore | - |
Formazione di Michael Wacker
| Swiss Federal Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Inositec AG
Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Health Technology |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
Tubulis GmbH
Tubulis GmbH Pharmaceuticals: MajorHealth Technology Tubulis GmbH engages in biotechnology company. The firm develops matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company was founded by Dominik Schumacher and Jonas Helma-Smets and is headquartered in Munich, Germany. | Health Technology |
- Borsa valori
- Insiders
- Michael Wacker
